Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease (CKD) and hepatic steatosis are two important clinical conditions that are frequently observed together, often in association with metabolic syndrome, and they contribute significantly to the global health burden. The FIB-4 index is a widely used non-invasive marker for assessing liver fibrosis, and its systemic implications have been investigated in recent years. The objective of this research was to assess the connection between FIB-4 and kidney function.
This prospective cohort study included 316 patients diagnosed with CKD and hepatic steatosis. Patients were divided into four groups (A–D) based on their FIB-4 scores. Using three-year follow-up data, the annual percentage changes in eGFR, liver enzymes, and hematological and metabolic parameters were calculated. These changes were first compared between groups, and Spearman’s correlation analysis was used to assess the relationships between variables across the entire cohort.
No significant differences were observed in eGFR values between the FIB-4 groups. However, Spearman’s correlation analysis revealed a weak but statistically significant negative correlation between FIB-4 and eGFR (r = -0.126, p = 0.025). FIB-4 was positively correlated with AST and AST/ALT ratio and negatively correlated with platelet count. No significant association was found between FIB-4 and ferritin, erythrocyte sedimentation rate, or liver size.
The modest yet noteworthy inverse relationship between FIB-4 and eGFR indicates that liver fibrosis might indirectly affect kidney function. Nevertheless, the FIB-4 index seems to be a limited indicator for predicting the progression of kidney disease. More extensive and prolonged studies are necessary to better understand this connection.
